Audience: Patients and the public. Published 18 November 2026 (AEDT).

A new once-daily tablet called Foundayo (orforglipron) has been added to the Australian Register of Therapeutic Goods. It was registered on 16 November 2026 as a prescription-only medicine. The manufacturer, Eli Lilly, has said it expects the tablets to be available on prescription in the coming days.

What it is approved for

Foundayo works in a similar way to injectable GLP-1 medicines such as semaglutide, but it is a small-molecule tablet rather than a protein. In Australia it is approved, alongside a healthy diet and physical activity, for weight management in adults with a body mass index (BMI) of 30 or more, or 27 or more with at least one weight-related condition such as high blood pressure, sleep apnoea or type 2 diabetes. It is also approved to treat type 2 diabetes in adults. Unlike the recently approved Wegovy tablet, it does not need to be taken on an empty stomach.

What the main trial found

The key weight trial, ATTAIN-1, included 3,127 adults with obesity or overweight who did not have diabetes, and ran for 72 weeks. At the highest dose, people lost an average of about 11% of their body weight, compared with about 2% on a placebo (dummy tablet). About 55 in every 100 people on the highest dose lost at least 10% of their weight, compared with 13 in every 100 on placebo. In a second trial in people with type 2 diabetes, average weight loss at the highest dose was about 10%, compared with about 2.5% on placebo.

Side effects

Side effects were mostly stomach-related and usually mild to moderate. At the highest dose, about 35 in 100 people had nausea (10 in 100 on placebo) and about 24 in 100 had vomiting (4 in 100 on placebo). Around 10 in 100 people on the highest dose stopped because of side effects, compared with 3 in 100 on placebo. Less common but more serious problems with this group of medicines include pancreatitis and gallbladder problems. It is not suitable during pregnancy.

Cost

Foundayo is not on the Pharmaceutical Benefits Scheme (PBS), so it is a private prescription. Lilly has suggested retail prices of about $250 to $370 for a 30-tablet pack, depending on the dose, though pharmacies set their own prices.

Limitations

The trials lasted 72 weeks, so longer-term effects, including effects on heart attacks and strokes, are not yet known. The trials were funded by the manufacturer and did not compare Foundayo directly with injectable medicines. The Australian Product Information was not yet available on the TGA website when this was written, so some of the details above come from the trial publication and the US prescribing information.

If you are interested in weight-management medicines, your regular GP can talk through whether any option suits your health and circumstances.

Prepared with AI assistance from the linked sources; not individually reviewed by a clinician. General information only, not individual medical advice.

Sources

Therapeutic Goods Administration: ARTG entry 521942, FOUNDAYO orforglipron 17.2 mg film coated tablet, ARTG date 16 November 2026 (accessed 18 November 2026, AEDT).
Wharton S, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med 2025;393:1796-1806 (accessed 18 November 2026, AEDT).
US prescribing information: FOUNDAYO (orforglipron) tablets, DailyMed (accessed 18 November 2026, AEDT).
RACGP newsGP: New oral GLP-1 to hit Australian shelves within days, 17 November 2026 (accessed 18 November 2026, AEDT).